Total Payments
$14,801
2024 Payments
$3,044
Companies
85
Transactions
710
Medicare Patients
12,515
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$11,916 (80.5%)
Other$1,531 (10.3%)
Consulting$1,000 (6.8%)
Education$353.66 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,916 | 680 | 80.5% |
| Long term medical supply or device loan | $1,531 | 17 | 10.3% |
| Consulting Fee | $1,000 | 1 | 6.8% |
| Education | $353.66 | 12 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,512 | 71 | $0 (2024) |
| AVEO Pharmaceuticals, Inc. | $1,108 | 6 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $934.70 | 60 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $852.73 | 53 | $0 (2024) |
| Exelixis Inc. | $689.26 | 13 | $0 (2024) |
| PFIZER INC. | $569.03 | 41 | $0 (2024) |
| Merck Sharp & Dohme LLC | $456.54 | 30 | $0 (2024) |
| Seagen Inc. | $453.47 | 26 | $0 (2023) |
| Amgen Inc. | $376.83 | 19 | $0 (2023) |
| Genentech USA, Inc. | $362.52 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,044 | 133 | Novartis Pharmaceuticals Corporation ($918.17) |
| 2023 | $3,691 | 109 | AVEO Pharmaceuticals, Inc. ($1,073) |
| 2022 | $2,109 | 112 | Novartis Pharmaceuticals Corporation ($638.03) |
| 2021 | $1,321 | 87 | AstraZeneca Pharmaceuticals LP ($141.84) |
| 2020 | $1,222 | 78 | Seagen Inc. ($172.84) |
| 2019 | $1,047 | 80 | Novartis Pharmaceuticals Corporation ($152.51) |
| 2018 | $839.73 | 49 | Novartis Pharmaceuticals Corporation ($204.94) |
| 2017 | $1,527 | 62 | Collegium Pharmaceutical, Inc. ($224.85) |
All Payment Transactions
710 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $0.33 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $8.52 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/09/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Oncology | ||||||
| 12/05/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: DESMOID TUMORS | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.44 | General |
| 11/22/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Oncology | ||||||
| 11/19/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/15/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.59 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.36 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Genentech USA, Inc. | Gazyva (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: BioOncology | ||||||
| 10/29/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $14.38 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 10/24/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA, ORGOVYX | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Oncology | ||||||
| 10/22/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.02 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 3,158 | 125,955 | $1.7M | $764,244 |
| 2022 | 36 | 3,153 | 141,155 | $1.7M | $698,611 |
| 2021 | 37 | 3,172 | 111,567 | $1.5M | $605,649 |
| 2020 | 46 | 3,032 | 203,738 | $1.8M | $738,321 |
Total Patients
12,515
Total Services
582,415
Medicare Billing
$2.8M
Procedure Codes
155
All Medicare Procedures & Services
155 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 24 | 8,460 | $253,800 | $156,541 | 61.7% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 13 | 4,753 | $218,638 | $121,054 | 55.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 274 | 663 | $126,009 | $67,929 | 53.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 51 | 69,750 | $92,768 | $61,248 | 66.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 408 | 844 | $109,720 | $61,085 | 55.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 311 | 768 | $161,280 | $51,400 | 31.9% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 32 | 8,051 | $169,071 | $46,686 | 27.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 59 | 347 | $120,062 | $40,265 | 33.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 28 | 3,820 | $57,300 | $23,855 | 41.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 531 | 2,179 | $26,148 | $18,304 | 70.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 524 | 2,134 | $57,618 | $16,240 | 28.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 97 | 110 | $63,690 | $16,008 | 25.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 56 | 494 | $29,640 | $12,596 | 42.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 93 | 97 | $38,412 | $10,765 | 28.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 105 | 105 | $20,370 | $9,667 | 47.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 109 | 740 | $37,000 | $8,821 | 23.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 78 | 152 | $38,152 | $8,666 | 22.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 84 | $10,164 | $5,520 | 54.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 18 | 88 | $14,872 | $4,959 | 33.3% |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 2023 | 11 | 11,520 | $7,834 | $4,925 | 62.9% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 21 | 58 | $11,890 | $4,711 | 39.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $7,670 | $3,360 | 43.8% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 30 | 166 | $11,288 | $2,888 | 25.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 21 | 34 | $2,720 | $1,685 | 61.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 43 | $3,225 | $1,057 | 32.8% |
About Dr. Randi Katz, D.O
Dr. Randi Katz, D.O is a Hematology healthcare provider based in Brick, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871540328.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Randi Katz, D.O has received a total of $14,801 in payments from pharmaceutical and medical device companies, with $3,044 received in 2024. These payments were reported across 710 transactions from 85 companies. The most common payment nature is "Food and Beverage" ($11,916).
As a Medicare-enrolled provider, Katz has provided services to 12,515 Medicare beneficiaries, totaling 582,415 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 155 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Brick, NJ
- Active Since 05/30/2006
- Last Updated 10/02/2024
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1871540328
Products in Payments
- KISQALI (Drug) $1,430
- FOTIVDA (Drug) $1,108
- CABOMETYX (Drug) $567.26
- OPDIVO (Biological) $541.44
- KEYTRUDA (Biological) $396.87
- Lenvima (Drug) $272.90
- ADCETRIS (Biological) $263.31
- Revlimid (Drug) $234.17
- CALQUENCE (Drug) $225.25
- Xtampza ER (Drug) $224.85
- PADCEV (Biological) $184.42
- SIR-Spheres Microspheres (Device) $177.30
- INJECTAFER (Drug) $164.11
- Stivarga (Drug) $163.88
- TAGRISSO (Drug) $162.73
- LONSURF (Drug) $162.69
- VERZENIO (Drug) $157.46
- INLYTA (Drug) $144.63
- PROMACTA (Drug) $138.55
- IMFINZI (Drug) $138.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.